Immutepjoins the ever-growing list of coronavirus stocks by announcing that it was granted a patent related to COVID-19 antibodies.
Immutep shares saw a nice gain in Wednesday’s session after the company released new data from its early-stage clinical trial in unresectable or metastatic melanoma patients.